Developing new paradigms for overcoming drug resistance in cancer using novel humanised mouse models

使用新型人源化小鼠模型开发克服癌症耐药性的新范例

基本信息

  • 批准号:
    MR/R017506/1
  • 负责人:
  • 金额:
    $ 158.74万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2018
  • 资助国家:
    英国
  • 起止时间:
    2018 至 无数据
  • 项目状态:
    已结题

项目摘要

Although there have been significant advances in the development of new treatments for cancer, where the drugs are now targeted at the genetic changes which drive tumour growth, major challenges still exist in translating this into long-term patient survival. In addition, drug side-effects particularly of new combination treatments, continue to be a major problem. The reason why the often dramatic patient responses, have not resulted in sustained long-term survival is because the tumours rapidly become resistant to the high concentrations of these very potent drugs. Whereas there is currently an enormous emphasis on cancer genomics, tumour cell heterogeneity, microenvironment, etc., there are essentially no studies on drug pharmacology i.e. how to use the new drugs optimally. Defining the pharmacology of emerging targeted anti-cancer drugs, rather than using dosing regimens based on MTD, has to be a fundamental component of developing new effective treatments for cancer, particularly for drug combinations. Understanding how best to use targeted agents can make the difference between success and failure of potentially promising new treatment regimens.Historical evidence, based particularly on the treatment of infectious diseases, has taught us that drug resistance can be overcome by either using combinations of drugs concomitantly, or by altering the drug dosing regimen. A major challenge for the improved treatment of cancer is therefore which combination of drugs should be used and what is the dosing schedule? Based on the enormous number of emerging targeted anti-tumour agents, it is impossible to address this challenge by clinical trial alone, and new pre-clinical models which are more predictive of patient responses are urgently needed. An important difference between animal models and humans is how drugs are handled by the body. This results in different rates of drug exposure and elimination and different drug metabolites. To address this problem, we have made a number of genetically altered mouse models in which drugs are metabolised in a manner similar to that observed in humans. It is the aim of this project to establish the potential of this model system to predict drug responses in man and to use this model to test whether drugs are still effective, alone or in combination, at doses which will be tolerated by patients. Our ultimate aim is to develop a computer-based model which will be used for the informed design of combination clinical trials which delay the onset of drug resistance. If successful, the application of the model systems developed in this programme could be of enormous benefit for the improved treatment of cancer, both in terms of patient survival and reduction in drug side-effects. The model validated in this programme could be of great for the development of new drugs, not only for the treatment of cancer but also for the treatment of other human diseases.
虽然癌症新疗法的开发取得了重大进展,其中药物现在针对驱动肿瘤生长的遗传变化,但在将其转化为长期患者生存方面仍然存在重大挑战。此外,药物副作用,特别是新的联合治疗,仍然是一个主要问题。为什么患者的反应往往是戏剧性的,但没有导致持续的长期生存的原因是因为肿瘤迅速变得对这些非常有效的药物的高浓度耐药。鉴于目前对癌症基因组学、肿瘤细胞异质性、微环境等的重视,基本上没有关于药物药理学的研究,即如何最佳地使用新药。定义新兴靶向抗癌药物的药理学,而不是使用基于MTD的给药方案,必须成为开发新的有效癌症治疗方法的基本组成部分,特别是对于药物组合。了解如何最好地使用靶向药物可以使潜在的有前途的新治疗方案的成功和失败之间的差异。历史证据,特别是基于感染性疾病的治疗,告诉我们,耐药性可以通过同时使用药物组合或通过改变药物给药方案来克服。因此,改善癌症治疗的一个主要挑战是应该使用哪种药物组合以及给药方案是什么?基于大量新兴的靶向抗肿瘤药物,仅通过临床试验不可能解决这一挑战,迫切需要更能预测患者反应的新临床前模型。动物模型和人类之间的一个重要区别是身体如何处理药物。这导致不同的药物暴露和消除速率以及不同的药物代谢物。为了解决这个问题,我们已经做了一些基因改变的小鼠模型,其中药物的代谢方式与在人类中观察到的相似。该项目的目的是建立该模型系统预测人体药物反应的潜力,并使用该模型测试药物在患者可耐受的剂量下单独或联合使用是否仍然有效。我们的最终目标是开发一个基于计算机的模型,该模型将用于延迟耐药性发生的联合临床试验的知情设计。如果成功的话,该计划中开发的模型系统的应用可能会对改善癌症治疗带来巨大的好处,无论是在患者生存还是减少药物副作用方面。在该项目中验证的模型可能对新药的开发非常重要,不仅用于治疗癌症,还用于治疗其他人类疾病。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Targeting Cellular DNA Damage Responses in Cancer: An In Vitro-Calibrated Agent-Based Model Simulating Monolayer and Spheroid Treatment Responses to ATR-Inhibiting Drugs.
  • DOI:
    10.1007/s11538-021-00935-y
  • 发表时间:
    2021-08-30
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    Hamis S;Yates J;Chaplain MAJ;Powathil GG
  • 通讯作者:
    Powathil GG
Referee report. For: Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism [version 1; peer review: 2 approved with reservations]
裁判报告。
  • DOI:
    10.5256/f1000research.135046.r160109
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Goldring C
  • 通讯作者:
    Goldring C
The Physics of Cancer - Research Advances
癌症物理学 - 研究进展
  • DOI:
    10.1142/11915
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Gerstman B
  • 通讯作者:
    Gerstman B
Referee report. For: Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism [version 2; peer review: 2 approved]
裁判报告。
  • DOI:
    10.5256/f1000research.145248.r167839
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Goldring C
  • 通讯作者:
    Goldring C
Quantifying ERK-activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling
使用数学模型量化对 BRAFV600E-MEK-ERK 级联抑制的 ERK 活性
  • DOI:
    10.1101/2021.04.20.440559
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Hamis S
  • 通讯作者:
    Hamis S
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Roland Wolf其他文献

Functional Characterization of the Transcription Silencer Element Located within the Human Pi Class Glutathione S-Transferase Promoter*
位于人 Pi 类谷胱甘肽 S-转移酶启动子内的转录沉默元件的功能表征*
Relative efficiency of three estimators in a polynomial regression with measurement errors
具有测量误差的多项式回归中三个估计量的相对效率
Dr. Thomas Friedberg (January 24, 1951–April 22, 2009)
  • DOI:
    10.1007/s00204-009-0468-1
  • 发表时间:
    2009-09-11
  • 期刊:
  • 影响因子:
    6.900
  • 作者:
    Roland Wolf;Franz Oesch
  • 通讯作者:
    Franz Oesch
Comparison of three estimators in a polynomial regression with measurement errors
多项式回归中三个估计量与测量误差的比较
  • DOI:
    10.5282/ubm/epub.1614
  • 发表时间:
    2001
  • 期刊:
  • 影响因子:
    0
  • 作者:
    A. Kukush;H. Schneeweiß;Roland Wolf
  • 通讯作者:
    Roland Wolf
Comparing Different Estimators in a Nonlinear Measurement Error Model
比较非线性测量误差模型中的不同估计器
  • DOI:
  • 发表时间:
    2002
  • 期刊:
  • 影响因子:
    0
  • 作者:
    A. Kukush;H. Schneeweiß;Roland Wolf
  • 通讯作者:
    Roland Wolf

Roland Wolf的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Roland Wolf', 18)}}的其他基金

Hazard Identification Platform to Assess the Health Impacts from Indoor and Outdoor Air Pollutant Exposures, through Mechanistic Toxicology
通过机械毒理学评估室内和室外空气污染物暴露对健康的影响的危害识别平台
  • 批准号:
    NE/W002078/1
  • 财政年份:
    2021
  • 资助金额:
    $ 158.74万
  • 项目类别:
    Research Grant
Defining the Deleterious Effects of Environmental Pollutants at a Mechanistic Level
从机制层面定义环境污染物的有害影响
  • 批准号:
    MR/R009848/1
  • 财政年份:
    2017
  • 资助金额:
    $ 158.74万
  • 项目类别:
    Research Grant
Metabolically Competent Stem Cell Systems: Novel Means to Implement 3Rs in Better Drug Safety Assessment
具有代谢能力的干细胞系统:在更好的药物安全性评估中实施 3R 的新方法
  • 批准号:
    G0700611/1
  • 财政年份:
    2008
  • 资助金额:
    $ 158.74万
  • 项目类别:
    Research Grant

相似国自然基金

脊髓新鉴定SNAPR神经元相关环路介导SCS电刺激抑制恶性瘙痒
  • 批准号:
    82371478
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
tau轻子衰变与新物理模型唯象研究
  • 批准号:
    11005033
  • 批准年份:
    2010
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目
HIV gp41的NHR区新靶点的确证及高效干预
  • 批准号:
    81072676
  • 批准年份:
    2010
  • 资助金额:
    33.0 万元
  • 项目类别:
    面上项目
强子对撞机上新物理信号的多轻子末态研究
  • 批准号:
    10675110
  • 批准年份:
    2006
  • 资助金额:
    36.0 万元
  • 项目类别:
    面上项目

相似海外基金

Shifting paradigms to emerging toxins in freshwater cyanobacterial blooms
淡水蓝藻水华中新出现的毒素的范式转变
  • 批准号:
    10912318
  • 财政年份:
    2023
  • 资助金额:
    $ 158.74万
  • 项目类别:
A Multi-Centre Non-Inferiority Randomized Controlled Trial of STOPping Cardiac MEDications in Patients with Normalized Cancer Therapy Related Cardiac Dysfunction - The STOP-MED CTRCD Trial
癌症治疗正常化相关心脏功能障碍患者停止心脏药物治疗的多中心非劣效随机对照试验 - STOP-MED CTRCD 试验
  • 批准号:
    489331
  • 财政年份:
    2023
  • 资助金额:
    $ 158.74万
  • 项目类别:
    Operating Grants
A pilot randomized, double-placebo controlled trial of sublingual or oral immunotherapy for tree nut allergy (TRADE)
舌下或口服免疫疗法治疗树坚果过敏的随机、双安慰剂对照试验(TRADE)
  • 批准号:
    479399
  • 财政年份:
    2023
  • 资助金额:
    $ 158.74万
  • 项目类别:
    Operating Grants
NEW AND SCALABLE PARADIGMS FOR DATA-DRIVEN MODEL PREDICTIVE CONTROL
数据驱动模型预测控制的新的、可扩展的范式
  • 批准号:
    2315963
  • 财政年份:
    2023
  • 资助金额:
    $ 158.74万
  • 项目类别:
    Standard Grant
New paradigms for rigorous modeling and fast solution of large-scale EMC problems
大规模 EMC 问题的严格建模和快速解决方案的新范例
  • 批准号:
    RGPIN-2018-05289
  • 财政年份:
    2022
  • 资助金额:
    $ 158.74万
  • 项目类别:
    Discovery Grants Program - Individual
New paradigms for designer materials
设计师材料的新范例
  • 批准号:
    RGPIN-2018-05011
  • 财政年份:
    2022
  • 资助金额:
    $ 158.74万
  • 项目类别:
    Discovery Grants Program - Individual
New paradigms in fibroblast-immune cells coordination in matrix homeostasis in health and disease
健康和疾病基质稳态中成纤维细胞-免疫细胞协调的新范例
  • 批准号:
    MR/W016796/1
  • 财政年份:
    2022
  • 资助金额:
    $ 158.74万
  • 项目类别:
    Fellowship
Electrical excitability in vascular smooth muscle: from rare disease to new paradigms
血管平滑肌的电兴奋性:从罕见疾病到新范例
  • 批准号:
    10614063
  • 财政年份:
    2022
  • 资助金额:
    $ 158.74万
  • 项目类别:
New Paradigms in Main Group Element Assembly and Catalysis
主族元素组装与催化新范式
  • 批准号:
    RGPIN-2019-04529
  • 财政年份:
    2022
  • 资助金额:
    $ 158.74万
  • 项目类别:
    Discovery Grants Program - Individual
New Paradigms for Edge Intelligence Hardware
边缘智能硬件的新范式
  • 批准号:
    RGPIN-2021-02660
  • 财政年份:
    2022
  • 资助金额:
    $ 158.74万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了